GlassScriptPhysician profile
Terah Crosson
NPI 1124687603
$1,363.61
in general payments reported to CMS, 2019-2025
28 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.20 · 2023: $400 · 2024: $754 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.41 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.14 | 2023-2024 | Enhertu, Andexxa, Lynparza |
| Myriad Genetic Laboratories, INC. | $114.34 | 2023 | Myrisk |
| Genmab U.S., INC. | $96.19 | 2024-2025 | Epkinly |
| Gilead Sciences, INC. | $95.00 | 2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $69.95 | 2024 | Keytruda, Welireg |
| Janssen Biotech, INC. | $66.53 | 2023-2024 | Darzalex, Tecvayli, Rybrevant |
| Lilly USA, LLC | $64.87 | 2024 | Retevmo, Jaypirca |
| Eisai INC. | $62.28 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $60.47 | 2023 | Imbruvica, Epkinly |
| Incyte Corporation | $54.39 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $36.31 | 2024 | Polivy, Lunsumio, Columvi |
| Dendreon Pharmaceuticals LLC | $35.75 | 2023-2024 | Provenge |
| Pfizer INC. | $34.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $32.97 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $32.41 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $23.83 | 2024 | Enhertu |
| Morphosys, US INC. | $21.21 | 2024 | Monjuvi |
| Sumitomo Pharma America, INC. | $19.34 | 2024 | Orgovyx |
| Sobi, INC | $18.02 | 2024 | |
| Springworks Therapeutics, INC. | $17.95 | 2024 | Ogsiveo |
| Pharmacosmos Therapeutics INC. | $17.17 | 2024 | Monoferric |
| Tersera Therapeutics LLC | $16.43 | 2023 | Zoladex |
| Recordati_rare_diseases_inc. | $15.35 | 2024 | Sylvant |
| Progenics Pharmaceuticals, INC. | $14.92 | 2024 | |
| Aveo Pharmaceuticals, INC. | $13.80 | 2023 | Fotivda |
| Seagen INC. | $13.37 | 2023 | Padcev |
| Amgen INC. | $13.17 | 2023 | Kyprolis, Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terah Crosson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.